In eukaryotes, cellular and systemic metabolism is primarily controlled by 2 mitochondrial activity. The peroxisome proliferator-activated receptor γ 3 coactivator 1α (PGC-1α) is a major regulator of mitochondrial biogenesis and 4 function. Furthermore, PGC-1α controls many of the phenotypic adaptations of 5 oxidative tissues to external and internal perturbations. In contrast, dysregulated 6 metabolic plasticity is involved in the etiology of numerous diseases. Accordingly, 7 modulation of PGC-1α levels and activity has recently been proposed as a 8 therapeutic option for several pathologies. However, pharmacological 9 interventions aimed at PGC-1α have to overcome inherent limitations of targeting 10 a coactivator protein. This review focuses on the recent breakthroughs in the 11 identification of physiological and pathophysiological contexts involving PGC-1α. 12
Introduction 1 2
Transcriptional changes in gene expression underlie the coordinated regulation 3 of biological programs. These changes are initiated and maintained by the 4 binding of regulatory protein complexes to DNA elements in the enhancer and 5 promoter regions of target genes. Traditionally, DNA-binding transcription factors 6 were thought to be the main regulators of gene expression. However, in recent 7 years, the importance of transcriptional coregulators in the coordination of the 8 expression of genetic programs has been appreciated [1, 2] . The family of 9 peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1) genes 10 illustrates how coactivators respond to environmental cues and subsequently 11 regulate biological processes in a tissue-specific and highly coordinated manner 12
[3-5]. All three members of this small gene family, PGC-1α, PGC-1β and PGC-13 related coactivator (PRC) are strong promoters of mitochondrial biogenesis and 14 oxidative metabolism [6] [7] [8] . In contrast to PRC that is ubiquitously expressed, 15 PGC-1α and PGC-1β are primarily found in oxidative tissues, including brain, 16 heart, kidney, muscle, liver, brown adipose tissue (BAT) and pancreas. In these 17 holds more promise for therapy in the liver. First, hepatic PGC-1α expression is 1 elevated in mouse models for type 1 and type 2 diabetes and probably 2 contributes to the unchecked glucose production and hyperglycemia in diabetes 3
[12]. Normalization of PGC-1α levels might thus help to control hepatic 4 gluconeogenesis in these patients. Individuals with acute hepatic porphyrias, 5 diseases caused by mutations in the heme biosynthetic pathway, often suffer 6 from fasting-induced acute attacks that can be alleviated by glucose and heme 7 administration [29] . PGC-1α has been identified as one of the main culprits in the 8 precipitation of acute porphyric attacks in fasting [27] . These attacks might be 9
prevented by pharmacological interventions that thwart the induction or activity of 10 PGC-1α [29, 30] . Furthermore, PGC-1α regulates the genes encoding 11 homocysteine synthesis enzymes in the fasted liver [31] . High plasma 12 homocysteine is an independent risk factor for the development of cardiovascular 13 diseases. Accordingly, inhibition of PGC-1α could result in a drop of plasma 14 homocysteine levels and thereby a reduction of the risk for cardiovascular 15 diseases [31] . Finally, the hepatitis B virus (HBV) uses the transcriptional 16 machinery that regulates the hepatic fasting response for amplification [32] . line exhibits increased anxiety [17] , whereas a second model shows a profound 7 hyperactivity [16] . Other behavioral changes include hind limb clasping, dystonic 8 posturing, an exaggerated startling response and stimulus-induced myoclonus 9
[16]. Besides the behavioral abnormalities, spongiform-like vacuolization events 10 are observed in the dorsolateral striatum [16] , the vicinity of pyramidal neurons 11 [17] , and more sporadically, in other regions of the brain of PGC-1α knockout 12 mice [16] . Furthermore, the substantia nigra and the CA1 neurons of the 13 hippocampus are more susceptible to degenerative events triggered by the 14 reactive oxygen species (ROS)-generating 1-methyl-4-phenyl-1,2,3,6-15 tetrahydropyridine (MPTP) and kainic acid, respectively, in these animals [34] . PGC-1α knockout suggest that PGC-1α is crucial for the maintenance of proper 4 striatal function [16, 38, 39] . A normalization of PGC-1α expression in the 5 striatum of Huntington's patients might thus constitute a promising therapeutic 6 option [40] [41] [42] . In addition, the wide-spread neuronal lesions and the 7 susceptibility to chemically-induced neurodegeneration in different regions of the 8 brain of PGC-1α knockout animals imply that PGC-1α has a broader role in 9 neuroprotection beyond that related to Huntington's disease [16, 34] . 10 11
Skeletal muscle 12 13
In the contracting muscle fiber, the main signaling pathways converge on PGC-14 1α to increase expression levels and the activity of this coactivator [3, 43, 44] 
12
In the heart, PGC-1α transcription is induced at birth and correlates with 13 metabolic maturation and remodeling [58] . As in other tissues, cardiac PGC-1α 14 strongly promotes mitochondrial function and fatty acid β-oxidation [59]. In 15 several mouse models for heart disease accompanied with a substrate switch 16 from fatty acid to glucose utilization, expression of PGC-1α is reduced [60] . At 17 baseline, heart function of PGC-1α knockout mice appears normal [17, 61] . 18
However, the cardiac reserve under stress conditions is impaired in mice with an 19 ablated PGC-1α gene [61] and accordingly, these mice have a diminished 20 cardiac capacity in exercise [17] . In addition, prolonged pressure overload by 21 transverse aortic constriction precipitates ventricular dysfunction and clinical 22 signs of heart failure in PGC-1α knockout animals [62] . Interestingly, ectopicexpression of PGC-1α in the heart at superphysiological levels also results in 1 cardiomyopathy and heart failure in mice [58] . 2 3 Therapeutic potential: Moderate elevation or normalization of PGC-1α expression 4 in the failing heart might be sufficient to switch substrate usage from glucose 5 back to fatty acids and restore adequate energy production [62] . Thereby, PGC-6 1α could be cardioprotective against certain insults [60] . In contrast, insulin-7 resistant hearts rely heavily on fatty acid oxidation and there, PGC-1α levels are 8 elevated [63] . It is unclear if upregulation of cardiac PGC-1α in insulin resistance 9
is an adaptive or a maladaptive process. In the former case, a reduction of PGC-10 1α expression should be the therapeutic goal. However, if the increase of PGC-11 1α is an adaptive process to cope with the excess amount of fatty acids, a further 12 elevation might be therapeutically beneficial [3, 60] . whether this induction is direct, secondary to other events or even sufficient to 20 contribute to the therapeutic effect of this class of drugs. 21 1 specificity towards binding partners (Fig. 2) . For example, PGC-1α is 2 phosphorylated by AMPK at two different sites [44] . Metformin, a clinically used 3 anti-diabetic drug mediates at least some of its therapeutic effect through 4 activation of AMPK. Furthermore, deacetylation of 13 lysine residues on PGC-1α 5 by the mammalian silencing information regulator 2-ortholog SIRT1 increases 6 PGC-1α activity and thereby targets gene expression in muscle and liver [72, 73] . 7
Resveratrol and other, more specific SIRT1 activators are promising drugs 8 against aging and aging-related diseases acting partially through PGC-1α [74] . 9
Other known modifications of PGC-1α include phosphorylations by p38 MAPK 10 drug targets for which specific activators and inhibitors can be designed. 14 Following the posttranslational modifications that modify the specificity of PGC-15 1α, the transcription of selective groups of target genes is altered (Fig. 2) 
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